
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. (VYGR)
WebsitePrice
Market cap
Next catalystExpected Q4 2026VY7523 — MAD study in early Alzheimer’s disease · Phase 1 dataSEC filing ↗
Cash
Chart & Events
Core Clinical
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
Other pipelines
Ab03
Antibody
Pathological tau
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
VCAP-101
ALPL
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
VCAP-102
ALPL
PreINDP1P2P3FilingApproved
Ab04
Antibody
Pathological tau
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved